22 Jul Ensoma
Daniel Leblanc, Chief Technology Officer
Oct. 6 | 4:45pm | FLW Ballroom G
Boston, MA
(Private)
Ensoma is developing potentially curative medicines for genetic diseases, immune disorders and cancer through precision in vivo cellular engineering. Our platform combines class-leading proprietary base editing and high-efficiency gene integration systems with high-capacity virus-like particles (VLPs) with an aim of provide one-time, durable genetic medicines in an outpatient procedure. The delivery system is based on VLPs that preferentially bind to hematopoietic stem cells (HSCs), efficiently deliver DNA to the nucleus while minimizing delivery other cell types, including the liver. With a 35-kilobase cargo capacity, these VLPs can carry a diverse range of sophisticated genomic engineering tools capable of changes from single base edits to large multi-gene insertions, along with control elements for HSC-lineage cell specific expression. Ensoma is supported by top-tier investors and a passionate team committed to a bold, global vision for genomic medicines. Ensoma is based in Boston.
